Abstract Details

Title Location of Intracerebral Hemorrhage and Cause of Death in the Longitudinal Follow-up of ICH Survivors in ERICH (ERICH-L) Study

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-031

Objective How location of intracerebral hemorrhage (ICH) affects long-term cause of death (COD)

Background The prognosis of ICH patients is dismal with a recent meta-analysis showing less than one-third survival at 5 years. COD beyond 30 days is poorly understood. Recent analysis from Longitudinal Follow-up of ICH Survivors (ERICH-L) study shows that incidence of cardiac death is second only to ICH itself. Risk factors for ICH are known to vary by location. We proposed to evaluate if COD varies by location of ICH.

Design/Methods The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) Study was a prospective, multi-center, case-control study of ICH. The ERICH-L study was composed of 959 subjects from the ERICH Study. Participants or surrogates were interviewed at 6-month intervals about recurrent stroke and COD for a median follow-up of 4.3 years. The COD categories included ICH, infection, cardiac, and other. Analyses were stratified into lobar and non-lobar ICH groups.

Results

Of the longitudinal study subjects, 167 died of which 108 had a known COD. Non-lobar ICH accounted for 71 (65.7%) of the total. Among non-lobar ICH patients, 21 died from recurrent ICH (29.6% of non-lobar), 15 died from cardiac causes (21.1%), 8 died from infection (11.3%), and 27 died from other causes (38.0%). Lobar hemorrhage accounted for 37 (34.3%) of the total. Among lobar ICH patients, 17 died from recurrent ICH (46.0% of lobar), 3 died from cardiac causes (8.1%), 2 died from infection (5.4%), and 15 died from other causes (40.5%). A chi-squared test showed no statistically significant difference between the two groups (p = 0.1532). No patients died from ischemic stroke.

Conclusions Cardiac death was a substantial portion of non-lobar ICH but was not statistically significant. The study may be underpowered to detect this difference. Limitations include recall bias. Surrogates may have been more likely to correctly recall certain COD than others.

Authors/Disclosures
Ian Bakk PRESENTER	Mr. Bakk has nothing to disclose.
	No disclosure on file
Tyler P. Behymer (University of Cincinnati College of Medicine)	No disclosure on file
	No disclosure on file
	No disclosure on file
Christina Kourkoulis	No disclosure on file
Elisheva R. Coleman, MD (University of Chicago Medical Center)	Dr. Coleman has nothing to disclose.
Russell Sawyer, MD (University of Cincinnati Neurology)	No disclosure on file
Matthew L. Flaherty, MD	Dr. Flaherty has received personal compensation for serving as an employee of Sense Diagnostics, Inc. Dr. Flaherty has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boeringher Engelheim. Dr. Flaherty has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Flaherty has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alexion. Dr. Flaherty has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for various law firms. Dr. Flaherty has stock in Sense Diagnostics, Inc. The institution of Dr. Flaherty has received research support from NINDS. Dr. Flaherty has received intellectual property interests from a discovery or technology relating to health care.
Alessandro Biffi, MD (Eli Lilly and Company)	Dr. Biffi has received personal compensation for serving as an employee of Eli Lilly And Company. Dr. Biffi has stock in Eli Lilly And Company.
Daniel Woo, MD, FAAN (University at Buffalo)	The institution of Dr. Woo has received research support from NIH.
Jonathan Rosand, MD (Massachusetts General Hospital)	Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Trustee with Columbia University that is relevant to AAN interests or activities.

��ɫ��

��ɫ��